Congratulations to Four Editorial Board Members of Hepatoma Research Recognized as Clarivate's "Highly Cited Researchers" for 2024
On November 19, 2024, Clarivate released its 2024 Highly Cited Researchers list, recognizing top researchers worldwide who have made a significant and far-reaching impact in their respective research fields. This year’s list includes 6,636 scientists from over 1,200 institutions across 59 countries and regions. Notably, 1,405 researchers from the mainland were included, representing 20.4% of the total.
Delightedly, four esteemed Editorial Board members of Hepatoma Research have been named to this prestigious list: Honorary Editor-in-Chief Prof. Shukui Qin, Editorial Board members Prof. Antonio Bertoletti, Prof. William C. Cho, and Prof. Richard S. Finn.
The editorial department of Hepatoma Research extends our heartfelt congratulations, deep respect, and best wishes to these outstanding scholars for their remarkable achievements.
Prof. Shukui Qin
Highly Cited Researcher in the field of Clinical Medicine – 2024
Cancer Centre of Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Prof. Shukui Qin is the Deputy Director of the People's Liberation Army (PLA) 81 Hospital (Nanjing, China), the Director of the Cancer Center of the Chinese PLA, and the Director of the National Drug Clinical Trial Agency of PLA 81 Hospital. He serves as the Executive Member of the Asian Clinical Oncology Society (ACOS), Chair of the Chinese Society of Clinical Oncology (CSCO), Council Member of the PLA Medical Science Commission (and Executive Member of its Oncology Society), Member of the Oncology Branch of the Chinese Medical Association, and Expert Committee Member of the National Tumor Standardized Diagnosis and Treatment Program under the Ministry of Health, where he also leads the Liver Cancer and Cancer Pain Expert Panels. Additionally, he serves as Vice President of the Beijing Xisike Clinical Oncology Research Foundation and Vice Chair of the Rehabilitation and Palliative Care Committee of the Chinese Anti-Cancer Association (CACA).
With decades of clinical practice and research, Prof. Qin has gained extensive expertise in the treatment of gastrointestinal cancers and their bone metastases, and has authored over 400 articles in peer-reviewed journals. He has been recognized with numerous awards at the ministerial and provincial levels, including four first-class prizes, two second-class prizes, seven third-class prizes, and two fourth-class prizes. Prof. Qin has also received special government allowances from the State Council of China and the PLA for his outstanding contributions. In addition to his clinical and research achievements, Prof. Qin serves as the Editor-in-Chief of two influential journals in China, Journal of Clinical Oncology and Clinical Oncology Tribune, further advancing the development of oncology in China.
Prof. Antonio Bertoletti
Highly Cited Researcher in the field of Cross-Field - 2024
Emerging Infectious Disease Program, Duke-NUS Medical School, Singapore, Singapore.
Prof. Antonio Bertoletti, recipient of the 2023 EASL International Recognition Award, is a distinguished expert in viral hepatitis with a specific focus on the immunopathogenesis of HBV infection. He serves as a Full Professor at the Emerging Viral Disease Program at Duke-NUS Medical School and holds an Adjunct Appointment at the Singapore Immunology Network (A*STAR). Prof. Bertoletti is a two-time recipient of the prestigious Singapore Translational Research Awards (2013, 2018).
In 2015, he founded Lion TCR Pte Ltd. (http://liontcr.com), a biotechnology company dedicated to developing immune-based therapies for virus-related cancers (HBV-HCC and EBV-associated malignancies) and chronic viral infections. The company specializes in immune therapies employing T cell receptor-engineered T cells that target viral antigens expressed by cancer cells. Lion TCR has been a pioneer in initiating and conducting Phase I and II clinical trials in Singapore and China for the treatment of HBV-related hepatocellular carcinoma (HCC) relapses in liver transplant patients and primary HCC cases. Currently, Prof. Bertoletti serves as Chairman of the Board and is a major shareholder.
His research focuses on advancing novel immunology-based therapies, including TCR-redirected T cells, for the treatment of chronic HBV infection and hepatocellular carcinoma. Additionally, he is actively involved in studying antiviral immunity in chronic HBV patients. Since the onset of the COVID-19 pandemic, his laboratory has made significant contributions to characterizing SARS-CoV-2-specific T cell immune responses in COVID-19 and SARS convalescent individuals, as well as in healthy subjects (Le Bert et al., Nature 2020, 584: 457-62).
Prof. William C. Cho
Highly Cited Researcher in the field of Cross-Field - 2024
Department of Clinical Oncology, Queen Elizabeth Hospital Hong Kong, Hong Kong, China.
Dr. Cho’s main research interests have been focusing on cancer studies to discover biomarkers for cancer diagnosis, treatment prediction, and prognostication. As a seasoned researcher, Dr. Cho has conducted cancer research using molecular biology, proteomics, genomics, immunology, and bioinformatics. His current H-index is about 93. Dr. Cho has published more than 600 peer-reviewed papers (Lancet, Lancet Oncology, Annals of Oncology, Lancet Gastroenterology & Hepatology, Advanced Science, Nature Communications, PNAS, Molecular Cancer, Journal of Thoracic Oncology, Journal of the National Cancer Institute, Journal of Extracellular Vesicles, Clinical Cancer Research, Clinical Chemistry, Theranostics, etc.) covering cancer biomarkers, proteomics, non-coding RNA, traditional Chinese medicine, and dozens of books (including “An Omics Perspective on Cancer Research”, “MicroRNAs in Cancer Translational Research”, “Drug Repurposing in Cancer Therapy: Approaches and Applications”, “Supportive Cancer Care with Chinese Medicine”, “Resistance to Anti-CD20 Antibodies and Approaches for Their Reversal”, etc.).
Prof. Richard S. Finn
Highly Cited Researcher in the field of Clinical Medicine – 2024
Department of Medicine, Division of Hematology/ Oncology, Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Prof. Richard S. Finn is a Professor of Clinical Medicine in the Division of Hematology/Oncology at the UCLA David Geffen School of Medicine and serves as the Director of the Signal Transduction Program at the Jonsson Comprehensive Cancer Center in Los Angeles, CA. He divides his professional time between clinical care and conducting laboratory and clinical research. Prof. Finn's research is primarily focused on the development of molecularly targeted agents and biomarkers for liver cancer and breast cancer.
He has played a central role as both a principal and sub-investigator in clinical trials investigating the application of targeted therapies in breast cancer and hepatocellular carcinoma. A key area of his work is identifying predictive biomarkers that can guide treatment decisions and optimize responses to novel therapeutic agents. Prof. Finn has been instrumental in the development of several groundbreaking therapeutics that have significantly advanced cancer treatment protocols, leading to paradigm shifts in clinical practice.
Prof. Finn is an active member of prominent organizations such as the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), and the European Society for Medical Oncology (ESMO). He has also served as the past president of the International Liver Cancer Association (ILCA) and currently contributes to the Editorial Board of Clinical Cancer Research.
More information can be available at：https://clarivate.com.cn/2024/11/19/highly-cited-researchers-2024/
Editor: Lily Ji
Language Editor: Catherine Yang
Production Editor: Ting Xu
Respectfully Submitted by the Editorial Office of Hepatoma Research
